# Rauwolscine **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/rauwolscine **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-04-01 **Evidence Score:** 2 / 10 **Category:** Compound **Also Known As:** 3-epi-yohimbine, α-yohimbine, alpha-yohimbine, isoyohimbine, Rauwolfia alkaloid, corynanthine, 3β-yohimbine ## Overview Rauwolscine is a yohimbine stereoisomer and indole alkaloid derived from plants such as Rauwolfia serpentina and Pausinystalia yohimbe, acting primarily as an alpha-2 adrenergic receptor antagonist. By blocking alpha-2 receptors, it may promote catecholamine-driven lipolysis and reduce appetite, though robust human clinical evidence remains limited. ## Health Benefits • May support weight management through reduced food intake (preliminary evidence from animal studies showing 3-6 hour appetite suppression in mice, PMID: 6145164) • Potential metabolic effects through alpha-2 adrenergic receptor antagonism (preclinical evidence only) • May influence [serotonin](/ingredients/condition/mood) signaling via 5-HT receptor interactions (in vitro binding studies only) • Possible [cardiovascular](/ingredients/condition/heart-health) effects through adrenergic modulation (limited to animal model data) • Note: All benefits are based on preclinical research with no human clinical trials available ## Mechanism of Action Rauwolscine competitively antagonizes alpha-2 adrenergic receptors, which normally suppress norepinephrine release and inhibit lipolysis in adipose tissue; blocking these receptors elevates circulating catecholamines and enhances triglyceride breakdown via hormone-sensitive lipase activation. It also exhibits agonist activity at 5-HT1A and 5-HT2B [serotonin](/ingredients/condition/mood) receptors, contributing to its appetite-modulating and mood-influencing effects. Additionally, rauwolscine has demonstrated affinity for dopamine D3 receptors and imidazoline receptors, though the functional significance of these interactions in humans has not been well characterized. ## Clinical Summary The most frequently cited evidence for rauwolscine's appetite-suppressive effects comes from rodent studies, including a 1984 mouse model (PMID: 6145164) showing a 3–6 hour reduction in food intake following acute administration. No large-scale randomized controlled trials in humans have been published specifically on isolated rauwolscine, making it difficult to extrapolate animal data to clinical outcomes. Most human research on alpha-2 antagonism in the context of fat loss has been conducted with the closely related compound yohimbine, which shares the same core mechanism; a double-blind crossover trial (n=20) found yohimbine increased [fat oxidation](/ingredients/condition/weight-management) by approximately 15% during exercise, suggesting a plausible parallel effect. Overall, the evidence base for rauwolscine in humans is preliminary and underpowered, and independent replication is necessary before efficacy claims can be substantiated. ## Nutritional Profile Rauwolscine (alpha-yohimbine) is a single indole alkaloid compound (C₂₁H₂₆N₂O₃, MW 354.44 g/mol), not a nutritional food source, and therefore does not possess a traditional macronutrient or micronutrient profile (no carbohydrates, fats, protein, fiber, vitamins, or minerals). It is a diastereomer (stereoisomer) of yohimbine, naturally occurring in the bark of Rauvolfia serpentina (Indian snakeroot) and Pausinystalia yohimbe at concentrations typically ranging from 0.01–0.5% of total alkaloid content in raw bark (substantially lower than yohimbine itself). Key bioactive properties: potent alpha-2 adrenergic receptor antagonist (Ki ≈ 1.3–5 nM at α2-adrenoceptors), with notable affinity for [serotonin](/ingredients/condition/mood) receptors including 5-HT1A (Ki ≈ 70 nM), 5-HT2A (Ki ≈ 40–100 nM), and 5-HT2B receptors. It also shows moderate affinity at dopamine D2 receptors. In commercial supplements marketed for fat loss, rauwolscine is typically dosed at 1–3 mg per serving, often standardized from Rauvolfia vomitoria or Pausinystalia yohimbe bark extracts. Bioavailability data in humans is extremely limited; however, as a lipophilic alkaloid it is expected to have reasonable oral absorption similar to yohimbine (oral bioavailability of yohimbine is ~22% due to significant first-pass hepatic [metabolism](/ingredients/condition/weight-management)). Rauwolscine is presumed to undergo hepatic CYP-mediated metabolism (likely CYP3A4 and CYP2D6 pathways by analogy with yohimbine). Half-life estimates in humans are not well-established but are speculated at approximately 2–5 hours based on structural similarity to yohimbine (t½ ≈ 0.5–2.5 hours). No established Recommended Daily Intake or Tolerable Upper Intake Level exists. The compound contains no caloric value and no essential nutrients. ## Dosage & Preparation No clinically studied dosage ranges for rauwolscine in humans are available. Preclinical studies used micromolar concentrations for in vitro assays but provide no guidance for human supplementation. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions Rauwolscine may cause dose-dependent side effects including elevated heart rate, increased [blood pressure](/ingredients/condition/heart-health), anxiety, [insomnia](/ingredients/condition/sleep), and gastrointestinal distress, mirroring the adrenergic stimulation profile of yohimbine. It carries a significant interaction risk with monoamine oxidase inhibitors (MAOIs), antihypertensive agents, stimulants such as caffeine or DMAA, and any norepinephrine reuptake inhibitors, as combined use can precipitate hypertensive crises or dangerous cardiovascular events. Rauwolscine is contraindicated in individuals with anxiety disorders, cardiac arrhythmias, hypertension, kidney disease, or a history of psychiatric illness. Pregnancy and breastfeeding safety has not been established, and use should be avoided in these populations; individuals should consult a physician before use, particularly those on prescription medications. ## Scientific Research No human clinical trials, randomized controlled trials, or meta-analyses on rauwolscine were identified in the available research. All evidence comes from preclinical studies including receptor binding assays, animal models (pithed rats, mice), and in vitro experiments examining alpha-2 adrenergic and [serotonin](/ingredients/condition/mood) receptor interactions. ## Historical & Cultural Context While rauwolscine occurs naturally in Rauwolfia plants used in traditional Ayurvedic medicine, no specific historical or traditional uses of isolated rauwolscine are documented in the available research. The compound has been studied primarily as an isolated bioactive rather than in ethnopharmacological contexts. ## Synergistic Combinations Yohimbine, caffeine, green tea extract, synephrine, L-tyrosine ## Frequently Asked Questions ### What is the difference between rauwolscine and yohimbine? Rauwolscine is a diastereomer of yohimbine, meaning it shares the same molecular formula (C21H24N2O3) but differs in the spatial arrangement of atoms at two stereocenters. Rauwolscine is reported to have approximately 4–5 times greater binding affinity for alpha-2 adrenergic receptors compared to yohimbine in some in vitro assays, which is why it is sometimes used at lower doses (typically 1–3 mg versus yohimbine's common range of 5–20 mg). Despite this higher receptor affinity, human pharmacokinetic and clinical outcome data directly comparing the two compounds are essentially absent. ### What is the typical rauwolscine dosage in supplements? Commercial pre-workout and fat-loss supplements typically include rauwolscine at dosages ranging from 1 to 3 mg per serving, reflecting its higher receptor binding potency relative to yohimbine. No human dose-ranging clinical trials have been conducted to establish a safe and effective therapeutic dose, so current dosing practices are largely extrapolated from yohimbine research and anecdotal reports. Users are generally advised to start at the lowest available dose (around 1 mg) to assess individual tolerance, particularly given its cardiovascular and anxiogenic side effect potential. ### Does rauwolscine actually help with fat loss? Rauwolscine's alpha-2 adrenergic antagonism theoretically promotes lipolysis by preventing norepinephrine feedback inhibition in adipose tissue, allowing greater catecholamine-driven fat breakdown via hormone-sensitive lipase. However, direct human clinical trial evidence for rauwolscine-specific fat loss is absent; the existing data are limited to animal studies and mechanistic in vitro work. Indirect support comes from yohimbine trials—such as a 2006 study in soccer players (n=20) showing a statistically significant reduction in body fat percentage—but this cannot be directly equated to rauwolscine outcomes without controlled human research. ### Is rauwolscine safe to take with caffeine? Combining rauwolscine with caffeine is common in pre-workout formulations but carries an elevated risk of additive cardiovascular and anxiogenic effects, including tachycardia, elevated blood pressure, and heightened anxiety, because both compounds stimulate sympathomimetic pathways. Caffeine inhibits phosphodiesterase and blocks adenosine receptors, compounding the norepinephrine elevation produced by rauwolscine's alpha-2 blockade. Individuals sensitive to stimulants, or those with pre-existing cardiovascular conditions, should avoid this combination entirely, and even healthy users should begin with low doses of each compound separately before combining them. ### What plants naturally contain rauwolscine? Rauwolscine is found as a minor alkaloid in Rauwolfia serpentina (Indian snakeroot), Pausinystalia yohimbe (yohimbe bark), and Aspidosperma species, where it co-occurs alongside the more abundant alkaloids yohimbine, corynanthine, and reserpine. In yohimbe bark extract, rauwolscine typically constitutes only a small fraction of total alkaloid content, often less than 5% by weight, which is why standardized or isolated rauwolscine is used when a higher-potency alpha-2 antagonist effect is desired. The varying alkaloid profiles across plant sources and extraction methods mean that crude yohimbe products deliver inconsistent rauwolscine concentrations. ### Is rauwolscine safe to take during pregnancy or while breastfeeding? Rauwolscine should be avoided during pregnancy and breastfeeding due to insufficient safety data and its pharmacological effects on adrenergic and serotonergic systems. No clinical studies have evaluated rauwolscine's effects on fetal development or breast milk composition, making it prudent to exclude this ingredient during these periods. ### Does rauwolscine interact with blood pressure medications or antidepressants? Rauwolscine may interact with blood pressure medications (especially alpha-blockers) and SSRIs/SNRIs due to its effects on adrenergic and serotonergic pathways, potentially causing hypotension or serotonergic complications. Anyone taking medications for hypertension, depression, or anxiety should consult a healthcare provider before using rauwolscine supplements. ### How strong is the clinical evidence supporting rauwolscine's effectiveness in humans? Most evidence for rauwolscine comes from animal studies and in vitro research, with very limited human clinical trials currently available. The preliminary appetite suppression findings are based primarily on mouse models, and human efficacy and safety data remain sparse, meaning supplement claims should be interpreted cautiously. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*